



What we do.

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

Precision Exhibiting at the 2011 Summer GOG Meeting

Precision will be exhibiting at the 2011 Summer GOG meeting being held in Philadelphia, PA. For more information, please speak to your Clinical Oncology Specialist.

New Publication on Endometrial Cancer and ChemoFx®

A new publication, titled, "Consistency of In Vitro Chemoresponse Assay Results and Population Clinical Response Rates in Endometrial Cancer," shows that ChemoFx® may provide clinically useful information to better optimize chemotherapy for women with endometrial cancer. The publication can be found in the April issue of the *International Journal of Gynecologic Cancer*. If you would like more information or a hard copy of this publication, please speak to your Clinical Oncology Specialist.

Precision Closes Partnership with Med Biogene to Commercialize 15 Gene Signature

Precision is in the research and development stages of commercializing a 15 gene signature for early stage NSCLC to be released in 2012. More information about this exciting new product will be released in the near future.

Precision Presents Data at ASCO

4 abstracts on Precision products were accepted by the American Society of Clinical Oncology (ASCO) for publication, 2 of which were chosen to be presented at the meeting, demonstrating data in gynecologic, breast and cervical cancers:

Acquired Drug Resistance in Gynecologic Cancer Detected by Drug Response Marker Testing¹

- 30 metachronous specimens were tested by the ChemoFx® Drug Response Marker in the primary and recurrent setting to observe shifts in drug response.
- A significant shift toward non-responsive was observed for single agents carboplatin and paclitaxel, which are commonly used as first-line therapy, however, a significant shift was not observed in other agents tested. This supports the utility of marker results obtained in the primary setting for assisting in treatment decisions when tissue is not available at the time of recurrence.

Multigene Predictors Developed on Breast Cancer Cell Lines to Predict Patient Chemotherapy Response: A Validation Study on the NSABP B-27 Trial²

- Multigene predictors of chemotherapy sensitivity were developed based on breast cancer cell lines exposed to combination chemotherapy regimens.
- This study shows promise in the prediction of preoperative chemotherapy response in early stage breast cancer. Prediction was especially good for doxorubicin/cyclophosphamide-treated ER-negative patients.

Chemo-Predictive Assay Directs Neoadjuvant Chemotherapy in Advanced Cervical Cancer³

- The goal of this study was to evaluate the utility of chemoresponse testing in cervical cancer.
- The study found that cervical cancer specimens submitted for chemoresponse testing are rarely contaminated and may provide clinically-impactful results, showing the possible utility of ChemoFx® in locally advanced cervical cancer.

In Vitro Chemosensitivity Assay for Patients with Gynecologic Sarcoma⁴

- This study describes the in vitro drug response of tumors from patients with gynecologic sarcoma and explores the clinical implication of in vitro assessment.
- The differential patterns of response observed in the gynecologic sarcoma subtypes suggest that chemoresponse testing may enable physicians to individualize chemotherapy regimens for their patients.

Full abstracts can be found through the ChemoFx® website at:

<http://www.chemofx.com/cancer-treatment/cancer-studiesbibliography.html>

¹J Clin Oncol 29: 2011 (suppl; abstr 5068); ²J Clin Oncol 29: 2011 (suppl; abstr 1029); ³J Clin Oncol 29: 2011 (suppl; abstr e15517); ⁴J Clin Oncol 29: 2011 (suppl; abstr e20513)

Promising data on the use of Chemosensitivity Testing in Non-Small Cell Lung Cancer (NSCLC) Reviewed at the Society of Surgical Oncology (SSO) Annual Meeting⁵

Drs. Rodney Landreneau and Matthew Schuchert from the University of Pittsburgh recently presented an abstract that examines whether the ChemoFx® Drug Response Marker can help choose between equivalent standard of care therapies for NSCLC patients. The physicians postulated that chemo-responsiveness of resected NSCLC specimens to commonly utilized "platinum-based" chemotherapy doublets may differ between patients. The doublets reviewed in this study were: cisplatin/gemcitabine, cisplatin/paclitaxel and cisplatin/pemetrexed.

Data demonstrated that while 35% of patient specimens evaluated in vitro were resistant to all three standard platinum doublets tested, 28% demonstrated a uniquely variable response, suggesting that ChemoFx® testing may help guide optimal selection of the platinum doublet for treatment, a factor that may be crucial to the patients' outcome.

⁵Schuchert, M.J., Cerfolio, R.J., et al. *Ann Surg Onc*. 2011; 18 (suppl 1; abstr 292)

www.chemofx.com • info@precisiontherapeutics.com • 1-800-547-6165

Precision Therapeutics is a CLIA-certified clinical laboratory

PT100028 ver06/09/11